| Literature DB >> 35200566 |
Sylvie D Lambert1,2, Lindsay R Duncan3, S Nicole Culos-Reed4,5, Laura Hallward3, Celestia S Higano6, Ekaterina Loban1,7, Anne Katz8, Manon De Raad1, Janet Ellis9, Melissa B Korman10, Carly Sears11, Cindy Ibberson1, Lauren Walker12, Eric Belzile1, Paramita Saha-Chaudhuri13, Helen McTaggart-Cowan14, Stuart Peacock14.
Abstract
BACKGROUND: Prostate cancer is the most common cancer diagnosis among men. Family caregivers (often female spouses) play a key role in ensuring patients' needs are met, frequently assuming their role with no formal training, which can contribute to a high burden. The purpose of this study was to pilot TEMPO-the first dyadic, Tailored, wEb-based, psychosocial and physical activity self-Management PrOgram for men with prostate cancer and their caregivers.Entities:
Keywords: behavior change; caregivers; dyadic interventions; dyads; e-Health interventions; physical activity; pilot study; prostate cancer; psychosocial needs; self-management
Mesh:
Substances:
Year: 2022 PMID: 35200566 PMCID: PMC8871005 DOI: 10.3390/curroncol29020067
Source DB: PubMed Journal: Curr Oncol ISSN: 1198-0052 Impact factor: 3.677
TIDieR guideline for reporting of interventions.
| Items | Description |
|---|---|
| Brief Name | Tailored, wEb-based, psychosocial and physical activity self-Management PrOgram ( |
| Why | |
| What (materials and procedures) | Dyads complete five modules: (a) identification of needs and priorities, (b) setting goals, (c) tracking progress and developing a coping plan, (d) strengthening support systems, and (e) maintaining behavior change beyond |
| Who provided | |
| How | Participants randomized to |
| Where | Each module becomes immediately available upon completion of the preceding module. If participants are not completing the modules at the expected pace (2 weeks per module), a maximum of two e-mail reminders are sent. |
| When and How much | As a self-directed intervention, |
| Tailoring | Dyads complete a needs assessment in Module 1 and based on their answers, they can prioritize issues and set goals to work on throughout |
| Modifications | Following our initial acceptability study: (a) new health library content was added to help participants engage in physical activity during COVID-19-related confinement, (b) streamlining the content of the modules, and (c) instead of releasing modules every two weeks, having them available as soon as the previous one is completed. |
A priori feasibility and acceptability benchmarks [39].
| Criteria | Benchmarks | Results |
|---|---|---|
|
| ||
| Recruitment rate | 8 dyads/month across sites | 6.1 dyads (or patients)/month |
| Refusal rate | <45% | 34% |
| Missing data | <10% | <10% |
| Protocol infringement | Amenable to change | None |
|
| ||
| Attrition | <25% across groups | 19% |
| Adherence | 75% of dyads adhere to modules | 45% |
| System usability (satisfaction) | High system usability reported | Above average |
|
| ||
| Effect size | 0.2 on the primary outcomes | Anxiety = 0.24 |
| Minimal clinically important difference improvement | 25% of participants improve on the primary outcomes by at least the minimal clinically important difference | Anxiety = yes |
Figure 1Flow diagram of recruitment and enrollment in TEMPO.
Patient and caregiver demographics.
| Characteristics | Men with Prostate Cancer | Caregivers | ||
|---|---|---|---|---|
| Control | Control | |||
|
| ||||
| ≤60 | 6 (23.1) | 6 (26.1) | 4 (25.0) | 6 (35.3) |
| ≥61 | 20 (76.9) | 17 (73.9) | 12 (75.0) | 11 (64.7) |
|
| ||||
| Male | 26 (100) | 26 (100) | 1 (6.2) | 1 (6.2) |
| Female | 15 (93.8) | 15 (93.8) | ||
|
| ||||
| English | 23 (88.5) | 21(91.3) | 15 (93.7) | 15 (88.2) |
| French | 0 | 1 (4.3) | 0 | 0 |
| Other | 3 (11.5) | 1 (4.3) | 1 (6.3) | 2 (11.8) |
|
| ||||
| Canada | 20 (76.9) | 17 (73.9) | 13 (81.3) | 12 (70.6) |
| Other | 6 (23.1) | 6 (26.1) | 3 (18.7) | 5 (29.4) |
|
| ||||
| High school or below | 0 | 2 (8.7) | 1(6.3) | 4 (23.5) |
| Post-secondary diploma | 10 (38.5) | 10 (43.5) | 4 (25.0) | 3 (17.6) |
| Undergraduate university | 6 (23.0) | 5 (21.7) | 6 (37.5) | 5 (29.4) |
| Graduate diploma | 10 (38.5) | 6 (26.1) | 5 (31.2) | 5 (29.4) |
|
| ||||
| Full time | 5 (19.2) | 7 (30.4) | 1 (12.5) | 2 (16.7) |
| Part time | 2 (7.7) | 1 (4.3) | 5 (62.5) | 2 (16.7) |
| Retired | 15 (57.7) | 14 (60.9) | 2 (25.0) | 7 (58.3) |
| Other | 4 (15.4) | 1 (4.3) | 0 (0.0) | 1 (8.3) |
| (Missing) | (8) | (5) | ||
|
| ||||
| Spouse/Partner | 23 (88.5) | 20 (87.0) | 16 (100) | 16 (94.1) |
| Other (friend, relative, etc.) | 3 (11.5) | 3 (13.0) | 0 | 1 (5.9) |
|
| 22 (84.6) | 20 (87.0) | 15 (93.8) | 16 (94.1) |
|
| ||||
| Married/common law | 22 (84.6) | 22 (95.7) | 15 (93.8) | 17 (100.0) |
| Other | 4 (15.4) | 1 (4.3) | 1 (6.2) | 0 |
|
| ||||
| <6 months | 1 (3.8) | 1 (4.3) | ||
| 6–12 months | 5 (19.2) | 2 (8.7) | ||
| 12–24 months | 16 (61.5) | 10 (43.5) | ||
| >24 months | 4 (15.4) | 10 (43.5) | ||
|
| ||||
| Early | 16 (61.5) | 14 (60.9) | ||
| Advanced | 8 (30.8) | 9 (39.1) | ||
| Don’t know | 2 (7.7) | 0 (0.0) | ||
| Surgery | 17 (65.4) | 16 (69.6) | ||
| Chemo | 2 (7.7) | 1 (4.3) | ||
| Radio | 13 (50.0) | 5 (21.7) | ||
| Hormonal | 13 (50.0) | 9 (39.1) | ||
| Brachytherapy | 5 (19.2) | 3 (13.0) | ||
| Other | 5 (19.2) | 3 (13.0) | ||
Baseline and post-test scores for primary and secondary outcomes for patients and caregivers.
| Outcomes | Men with Prostate Cancer | Caregivers | Combined Effect Size * | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Follow-Up | Effect Size | Baseline | Follow-Up | Effect Size | ||||||
| Control | Control | Control | Control | ||||||||
| Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) | ||||
|
| |||||||||||
|
| |||||||||||
| Mental | 48.0 (8.5) | 46.1 (9.2) | 49.3 (10.3) | 46.8 (10.8) | 0.23 | 52.5 (7.1) | 50.4 (9.3) | 54.7 (5.3) | 47.6 (9.6) | 0.87 | 0.38 |
| Physical | 50.2 (9.3) | 49.3 (12.2) | 52.6 (6.1) | 49.1 (12.5) | 0.35 | 52.7 (8.0) | 51.6 (7.9) | 51.1 (9.9) | 49.2 (8.6) | 0.21 | 0.30 |
| (missing) | (0) | (0) | (0) | (0) | (0) | (1) | (1) | (0) | |||
|
| 5.5 (3.4) | 6.3 (4.1) | 4.5 (4.2) | 5.3 (4.7) | 0.19 | 5.0 (4.1) | 4.6 (3.6) | 3.4 (2.8) | 4.8 (3.3) | 0.43 | 0.24 |
| (missing) | (0) | (0) | (0) | (0) | (0) | (0) | (1) | (0) | |||
|
| |||||||||||
|
| 3.6 (3.4) | 5.0 (4.2) | 3.7 (4.4) | 4.8 (4.3) | 0.26 | 2.3 (2.5) | 3.1 (2.2) | 1.2 (1.6) | 3.4 (3.0) | 0.88 | 0.31 |
| (missing) | (0) | (0) | (0) | (0) | (0) | (0) | (1) | (0) | |||
|
| 13.3 (6.2) | 13.4 (6.7) | 12.8 (7.1) | 12.4 (8.1) | 0.05 | 12.3 (7.7) | 14.7 (6.0) | 11.0 (5.5) | 12.1 (5.3) | 0.35 | 0.04 |
| (missing) | (1) | (1) | (1) | (1) | (1) | (2) | (1) | (1) | |||
|
| |||||||||||
| Positive engagement | 3.3 (0.5) | 3.1 (0.6) | 3.4 (0.6) | 3.2 (0.6) | 0.33 | 3.4 (0.4) | 3.1 (0.4) | 3.4 (0.5) | 3.1 (0.4) | 0.90 | 0.46 |
| Skill acquisition | 3.0 (0.4) | 3.1 (0.4) | 3.3 (0.4) | 3.1 (0.5) | 0.44 | 3.1 (0.5) | 2.5 (0.4) | 2.9 (0.4) | 2.6 (0.4) | 0.75 | 0.48 |
| Constructive attitudes | 3.4 (0.5) | 3.3 (0.7) | 3.4 (0.6) | 3.3 (0.7) | 0.15 | 3.3 (0.4) | 3.0 (0.4) | 3.3 (0.4) | 3.3 (0.4) | 0.00 | 0.14 |
| Self-monitoring | 3.3 (0.3) | 3.2 (0.4) | 3.4 (0.4) | 3.3 (0.4) | 0.25 | 3.3 (0.4) | 2.9 (0.5) | 3.2 (0.4) | 3 (0.5) | 0.43 | 0.29 |
| Health services navigation | 3.3 (0.4) | 3.4 (0.5) | 3.3 (0.5) | 3.4 (0.6) | −0.18 | 3.2 (0.4) | 2.7 (0.4) | 3.1 (0.1) | 2.6 (0.7) | 0.92 | 0.26 |
| Social integration and support | 3.1 (0.5) | 3.1 (0.6) | 3.2 (0.6) | 3.1 (0.6) | 0.17 | 3.1 (0.5) | 2.7 (0.6) | 3.1 (0.8) | 2.6 (0.6) | 0.73 | 0.34 |
| (missing) | (0) | (0) | (1) | (1) | (2) | (7) | (1) | (0) | |||
|
| |||||||||||
| Sufficient information | 3.0 (0.5) | 3.0 (0.6) | 3.1 (0.5) | 3.1 (0.6) | 0.00 | 3.2 (0.5) | 3.2 (0.5) | 3.4 (0.5) | 3.1 (0.7) | 0.48 | 0.04 |
| Actively managing | 3.1 (0.6) | 3.1 (0.4) | 3.2 (0.5) | 3.1 (0.5) | 0.20 | 3.2 (0.5) | 3.1 (0.6) | 3.4 (0.6) | 3.0 (0.7) | 0.61 | 0.38 |
| (missing) | (1) | (1) | (1) | (1) | (1) | (1) | (1) | (1) | |||
| 1894 (1919) | 2365 (3313) | 2521 (1471) | 2253 (1969) | 0.17 | 1953 (2210) | 1410 (1082) | 2020 (1812) | 1713 (1870) | 0.17 | 0.15 | |
|
| 4.2 (2.1) | 3.7 (2.2) | 4.7 (2.0) | 3.5 (1.8) | 0.63 | 4.8 (2.0) | 4.3 (1.9) | 5.0 (1.4) | 4.6 (1.9) | 0.24 | 0.48 |
| (missing) | (1) | (2) | (1) | (1) | (1) | (2) | (1) | (2) | |||
|
| 4.6 (2.0) | 3.9 (2.1) | 4.8 (1.7) | 4.1 (1.5) | 0.44 | 5.2 (1.8) | 4.8 (1.9) | 4.9 (1.2) | 4.4 (1.5) | 0.36 | 0.38 |
| (missing) | (3) | (3) | (1) | (1) | (3) | (4) | (3) | (4) | |||
|
| 73.0 (21.5) | 66.2 (20.4) | 78.5 (16.5) | 61.6 (26.2) | 0.76 | 75.7 (20.1) | 70.9 (16.6) | 81.2 (13.9) | 68.1 (21.3) | 0.71 | 0.72 |
| (missing) | (4) | (2) | (1) | (1) | (1) | (2) | (1) | (1) | |||
|
| 124.9 (24.7) | 128.0 (19.5) | 132.8 (14.8) | 121.5 (21.5) | 0.61 | 136 (22.1) | 121.5 (18.8) | 135.2 (19.3) | 126.1 (17.1) | 0.50 | 0.63 |
| (missing) | (4) | (2) | (1) | (1) | (1) | (2) | (1) | (2) | |||
|
| 49.4 (12.2) | 47.9 (7.5) | 53.2 (6.4) | 51.0 (8.2) | 0.30 | 54.5 (9.2) | 48.5 (6.7) | 54.7 (7.6) | 51.3 (5.5) | 0.57 | 0.36 |
| (missing) | (7) | (6) | (9) | (11) | (6) | (6) | (7) | (4) | |||
Note. Data presented are for the entire sample, including dyads and men with prostate cancer who participated alone. * = Effect Sizes are provided for each man and caregiver, as well as the combined effect size (last column). Clinical significance is based on the combined ES. SD = standard deviation.